In a landmark FDA ruling, Ocrevus became the first DMT approved for the treatment of PP-MS in March 2017. Although the drug’s efficacy appears more modest than in patients with relapsing forms of MS, the combination of proven clinical benefits and a positive safety profile (to date) yields a highly compelling product for a deeply underserved population. Even so, many questions remain about exactly how it will fit into the progressive MS treatment algorithm. DRG’s launch tracking series will examine how the perception and performance of Ocrevus evolves through Year 1 with an MS prescriber base that has hitherto struggled to treat PP-MS.

What you will learn in this content

  • What is the awareness of, familiarity with, and perceptions related to Ocrevus among U.S. neurologists?
  • For which patients are neurologists prescribing Ocrevus, what are the reasons for prescribing, and how satisfied are they with Ocrevus?
  • What promotional messages and activities are Genentech/Roche employing in support of the Ocrevus launch in PP-MS?
  • How does the trial and adoption of Ocrevus in PP-MS compare to Ocrevus and other recent product launches in the saturated relapsing MS market? How do adopters and nonadopters in PP-MS compare across key metrics?

Product description

Launch Tracking: Ocrevus Wave 1 (US) Primary Progressive Multiple Sclerosis is a three-wave series based on primary research data collected at 1, 6, and 12 months postcommercial launch with U.S. physicians. The research captures physicians’ awareness, perceptions, and usage of the launched product, as well as anticipated future trends. Insight is also provided on promotional efforts, prescriber and nonprescriber profiles, and benchmarking against other launched agents.

Table of contents

  • Ocrevus PP-MS Launch Tracking Wave 1 (US)
    • Key Findings
      • Key Findings
    • Benchmarking Ocrevus Launch Success vs. Other Launched Drugs
      • Uptake of Ocrevus in PP-MS Is Impressive at One Month Postlaunch
    • Prescriber and Nonprescriber Profiles
      • Differences Between Ocrevus Prescribers and Nonprescribers for PP-MS
    • Ocrevus Awareness and Perceptions
      • Unaided and Aided Awareness of Ocrevus
        • Awareness of Ocrevus One Month Postlaunch Is Substantial
      • Familiarity with Ocrevus
        • Few Neurologists Are Unfamiliar with Ocrevus
      • Sources of Familiarity with Ocrevus
        • Word of Mouth from Neurologist Colleagues Aids Familiarity with Ocrevus
      • Initial Reaction to and Interest in Ocrevus
        • Neurologists with a Favorable Impression of Ocrevus Express Interest to Learn More
      • Impressions of Ocrevus
        • Surveyed Neurologists' Favorable Impression of Ocrevus's Efficacy in PP-MS Outweighs Perceptions of Risk
      • Prescriber and Nonprescriber Profiles
        • Ocrevus Nonprescribers Appear More Risk-Averse Than Prescribers
    • Ocrevus Trial and Use
      • Willingness to Prescribe Ocrevus
        • Efficacy Drives High Willingness to Prescribe Ocrevus to PP-MS Patients
      • Number of Patients Currently Receiving Ocrevus
        • Two-Thirds of Neurologists Have Already Prescribed Ocrevus to PP-MS Patients at One Month Postlaunch
      • Reasons for Not Yet Prescribing Ocrevus
        • Safety Concerns, Familiarity, and Cost to Patients Are the Major Dampers on Ocrevus Uptake in PP-MS
      • Anticipated Ocrevus Use
        • Wave 1 Respondents Project That Ocrevus Will Rapidly Become the Patient-Share Leader in PP-MS
      • Ocrevus Performance on Key Attributes
        • Surveyed Neurologists Report Early Satisfaction on Key Ocrevus Attributes
    • Effectiveness of Face-to-Face Detailing for Ocrevus
      • Ocrevus Sales Representative Frequency and Reach
        • Nearly One-Quarter of Neurologists Met with an Ocrevus Sales Representative Within the Month Preceding Survey Fielding
      • Satisfaction with Ocrevus Sales Representative
        • Neurologists Are Highly Satisfied with Ocrevus Sales Representatives
      • Ocrevus Message Recall
        • Ocrevus's Approval for PP-MS is a Key Message in Early Detailing Efforts
    • Methodology
      • Primary Market Research Methodology
    • Appendix
      • Bibliography

Author(s): Sarah Soucy; Jonathan Searles

Sarah Soucy, is a Business Insights Analyst with the central nervous system/ophthalmology disorders group at Decision Resources Group. She has authored primary research and insights for dry and wet age-related macular degeneration and multiple sclerosis. Prior to joining DRG, Ms. Soucy spent six years on the client side as a scientist at Pfizer in the inflammation and immunology research group with both in vitro and in vivo experience. She earned her in Animal Science with a Bioscience and Technology option and her in Nutritional Sciences from the University of New Hampshire, Durham, where she studied disordered metabolism

Jonathan ;Searles is a Senior Director in the CNS/Ophthalmology unit at DRG, overseeing the neurology research stream. Prior to joining DRG, ;Searles received a degree, summa cum laude, from Brandeis University; during this time, Mr. Searles conducted research projects at the Harvard University Peabody Museum and at Brandeis.


Related Reports

Multiple Sclerosis | Access and Reimbursement | US | 2017`

The dynamic multiple sclerosis (MS) market in the United States features more than a dozen high-cost branded (and one generic) disease-modifying therapies (D...

View Details

Multiple Sclerosis | Access & Reimbursement | Detailed, Expanded Analysis (US)

The shifting multiple sclerosis (MS) therapy market continues to evolve as new disease-modifying therapies (DMT

View Details

Multiple Sclerosis | Landscape & Forecast | Disease Landscape & Forecast

The maturing yet highly lucrative market for multiple sclerosis (MS) disease-modifying therapies (DMTs) will...

View Details

Multiple Sclerosis | Treatment Algorithms | Claims Data Analysis | US | 2018

With more than a dozen disease-modifying therapies (DMTs) available to treat multiple sclerosis (MS), the trea...

View Details